Barriers to Genetic Testing in Vascular Malformations.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Original Publication: Chicago, IL : American Medical Association, [2018]-

Vascular Malformations*; Child ; Humans ; Genetic Testing ; Alleles ; Ambulatory Care Facilities ; Educational Status

Importance: Vascular malformations (VMs) are rare disorders of vasculogenesis associated with substantial morbidity. Improved understanding of their genetic basis is increasingly guiding management, but logistical barriers to obtaining genetic testing in patients with VM may constrain treatment options.
Objectives: To examine the institutional mechanisms for and obstacles to obtaining genetic testing for VM.
Design, Setting, and Participants: This survey study invited members of the Pediatric Hematology-Oncology Vascular Anomalies Interest Group, representing 81 vascular anomaly centers (VACs) serving individuals up to 18 years of age, to complete an electronic survey. Respondents were mostly pediatric hematologists-oncologists (PHOs) but included geneticists, genetic counselors, clinic administrators, and nurse practitioners. Responses that were received between March 1 and September 30, 2022, were analyzed with descriptive methods. Requirements for genetic testing by several genetics laboratories were also reviewed. Results were stratified by size of the VAC.
Main Outcomes and Measures: Vascular anomaly center and associated clinician characteristics and practice patterns for ordering and obtaining insurance approval for genetic testing for VMs were collected.
Results: Responses were received from 55 of 81 clinicians, for a response rate of 67.9%. Most respondents were PHOs (50 [90.9%]). Most respondents (32 of 55 respondents [58.2%]) replied that they order genetic testing on 5 to 50 patients per year and reported a genetic testing volume increase of 2- to 10-fold over the past 3 years (38 of 53 respondents [71.7%]). Most testing was ordered by PHOs (35 of 53 respondents [66.0%]), followed by geneticists (28 [52.8%]) and genetic counselors (24 [45.3%]). In-house clinical testing was more common at large and medium-sized VACs. Small VACs were more likely to use oncology-based platforms, which potentially miss low-frequency allelic variants in VM. Logistics and barriers varied by size of the VAC. Obtaining prior authorization was the duty shared among PHOs, nurses, and administrative staff, but the burden of insurance denials and appeals were on PHOs (35 of 53 respondents [66.0%]). Lack of administrative support; unclear institutional, insurance, and laboratory requirements; and lack of clinician education were barriers to genetic testing at VACs of all sizes. The effort to obtain genetic testing for patients with VM, compared with patients with cancer, was perceived as excessive, despite genetic testing being considered standard of care for this population.
Conclusions and Relevance: Results of this survey study showed the barriers to genetic testing for VM across VACs, described differences between VACs based on size, and proposed multiple interventions to support clinicians ordering genetic testing for VM. The results and recommendations should have broader application to clinicians caring for patients for whom molecular diagnosis is important to medical management.

J Vasc Anom (Phila). 2022 Mar;3(1):. (PMID: 36284525)
J Invest Dermatol. 2018 Apr;138(4):957-967. (PMID: 29174369)
JAMA Surg. 2021 Aug 1;156(8):785-786. (PMID: 33825811)
Pediatr Blood Cancer. 2018 Jan;65(1):. (PMID: 28727248)
JAMA Dermatol. 2019 Feb 1;155(2):256-257. (PMID: 30566190)
Tech Vasc Interv Radiol. 2019 Dec;22(4):100629. (PMID: 31864536)
Nature. 2018 Jun;558(7711):540-546. (PMID: 29899452)
Pediatr Blood Cancer. 2022 Aug;69 Suppl 3:e28863. (PMID: 36070214)
Am J Clin Pathol. 2018 Apr 25;149(6):530-535. (PMID: 29635311)
Nat Biotechnol. 2022 Jan;40(1):20-21. (PMID: 34997245)
Plast Reconstr Surg. 2018 May;141(5):709e-717e. (PMID: 29697621)
Nat Med. 2019 Jul;25(7):1116-1122. (PMID: 31263281)
Pediatrics. 2020 Dec;146(6):. (PMID: 33219052)
Circ Res. 2021 Jun 25;129(1):155-173. (PMID: 34166070)
Am J Clin Dermatol. 2020 Oct;21(5):657-668. (PMID: 32557381)
Front Pediatr. 2020 Oct 19;8:579591. (PMID: 33194911)
EMBO Mol Med. 2020 Oct 7;12(10):e12324. (PMID: 32894644)
Hum Mol Genet. 2018 Sep 15;27(18):3233-3245. (PMID: 29905864)
Pediatrics. 2020 Sep;146(3):. (PMID: 32859736)
Semin Intervent Radiol. 2017 Sep;34(3):239-249. (PMID: 28955113)
Genet Med. 2019 May;21(5):1189-1198. (PMID: 30270358)
J Clin Invest. 2018 Apr 2;128(4):1496-1508. (PMID: 29461977)
Eur J Hum Genet. 2023 Feb;31(2):142-147. (PMID: 36471117)
Hematol Oncol Clin North Am. 2019 Jun;33(3):455-470. (PMID: 31030813)
Cold Spring Harb Mol Case Stud. 2021 Dec 9;7(6):. (PMID: 34649967)
Genes Chromosomes Cancer. 2019 Aug;58(8):541-550. (PMID: 30677207)
Hum Mol Genet. 2023 Jan 6;32(2):276-289. (PMID: 35972810)
J Community Genet. 2022 Oct;13(5):477-485. (PMID: 33453057)
Genet Med. 2021 Jan;23(1):123-130. (PMID: 32884133)
Front Pediatr. 2022 May 23;10:857436. (PMID: 35676905)
J Exp Med. 2022 Mar 7;219(3):. (PMID: 35080595)
Pediatrics. 2016 Feb;137(2):e20153257. (PMID: 26783326)
Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24. (PMID: 21445948)

Date Created: 20230523 Date Completed: 20230525 Latest Revision: 20230526

20231215

PMC10208144

10.1001/jamanetworkopen.2023.14829

37219903